Bisphenol A Controlled Exposure Study
- Bisphenol A (BPA) is a chemical that is used primarily to make plastics, resins, and thermal paper. Most people are exposed daily to low levels of BPA that leaches into food and water from plastic products, including water and baby bottles. However, not all of the risks of BPA are known. Researchers want to learn more about how BPA acts in the body, and how the body gets rid of BPA.
- To study controlled exposure to BPA and its effects on the body.
- Healthy, non-obese volunteers between 25 and 45 years of age.
- Participants will have five visits over about 2 to 4 weeks for this study.
- At the first visit, participants will be screened with a physical exam and blood and urine tests. They will complete a questionnaire about exposure to BPA-containing products. They will also receive a list of medications that should not be taken during the study period.
- The second visit will last about 13 hours. Participants will fast for 8 hours before the visit. They will then have a single dose of d-BPA (a modified form of BPA that is easier to study in the body). Regular blood samples will be taken over the 13-hour visit. All urine will also be collected. Participants will receive breakfast and lunch during the visit.
- Participants will have three follow-up visits. They will collect and store all of their urine between each follow-up visit. Blood samples will be collected at the follow-up visits.
|Study Design:||Allocation: Non-Randomized
Endpoint Classification: Pharmacokinetics/Dynamics Study
Intervention Model: Single Group Assignment
Masking: Open Label
|Official Title:||Bisphenol A (BPA) Pharmacokinetic (PK): Controlled Exposure Study|
- Pharmacokinetics of d-BPA and d-BPA conjugates in blood and urine over 5 days.
|Study Start Date:||March 2012|
|Estimated Study Completion Date:||December 2015|
|Estimated Primary Completion Date:||December 2015 (Final data collection date for primary outcome measure)|
Other: deuterated-Bisphenol A (d-BPA)
Bisphenol A (BPA) is utilized primarily in the manufacture of polycarbonate plastic and epoxy resins, which are widely used in the fabrication of baby bottles and food can linings. Consequently, human exposures to BPA are widespread. However, there is still uncertainty about the extent and nature of these exposures. This pharmacokinetic (PK) study is aimed at refining our understanding of the metabolism and excretion of BPA following two different routes of administration. This investigation is also intended to help resolve current controversies in BPA risk assessment. We will administer 100 g/kg body weight (bw) of deuterated BPA (d- BPA) orally and/or dermally, in up to 50 participants, with comparable numbers of men to women, and collect blood and urine for measurements of d-BPA and d-BPA conjugates at selected time points over a three day period post-dosing. The use of d-BPA will allow the detection of the administered BPA to be distinguished from background BPA. The primary endpoint of the study is detection of measurable d-BPA and d-BPA conjugates in blood and urine after administration of a single dose of 100 g/kg bw d-BPA applied orally and/or dermally. Participants will be given an option to complete either one or both phases of the study, the exposure visits separated by a period of at least 4 weeks. Dose selection was based on balancing the need for detectable levels of BPA in blood and urine to meet the objective and the need to minimize human subject risk. Data from the first 3 participants in the study, who received oral d-BPA, confirmed dosing during the oral pilot phase was sufficient in capturing measurable d-BPA in blood and urine and will continue at 100 g/kg bw of d-BPA for oral dosing. Dermal exposure will consist of a pilot phase for this route of administration comprising 4 participants to assess whether 100 g/kg bw of d-BPA applied to the skin is sufficient to obtain measurable d-BPA in blood and/or urine in order to establish PK parameters and to evaluate whether the time points are appropriate and necessary. If needed, the dermal pilot phase will be repeated using an ethanol solution rather than a carboxymethylcellulose suspension. The design includes sufficient sampling of blood and urine to define relevant PK parameters, including the rate of BPA absorption, plasma elimination rate, area under the curve (AUC) and apparent clearance, half-life, the urinary excretion rate, and the fractional metabolic clearance of the glucuronide and sulfate conjugates.
Please refer to this study by its ClinicalTrials.gov identifier: NCT01573429
|Contact: Lisa B Murphy||(919) firstname.lastname@example.org|
|Contact: Shepherd H Schurman, M.D.||(919) email@example.com|
|United States, North Carolina|
|NIEHS Clinical Research Unit (CRU)||Recruiting|
|Research Triangle Park, North Carolina, United States|
|Contact: Lisa Murphy 919-541-9839 firstname.lastname@example.org|
|Principal Investigator:||Shepherd H Schurman, M.D.||National Institute of Environmental Health Sciences (NIEHS)|